Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 25, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for May 25, 2005 Subscribe to this News Feed      
 

Illegal Drug Being Promoted by Small Group

Backed by pro-drug advocates, the dangerous club drug ecstasy is being tested on patients in therapy sessions

(PRWEB) May 25, 2005 -- The connection between psychiatry and drugs is not new. In fact, many psychiatric diagnoses call for drugs as part of their treatment protocol. Drug use in the psychiatric community has been around for decades, including experimental uses of everything from amphetamines and antidepressants for kids to the early exploration of LSD.

Today the trend continues and the latest abhorrence comes from a psychiatrist in South Carolina who is using the illegal drug ecstasy (MDMA) in a study of people whove had difficult situations in life and are having trouble dealing with them. A label has been created for these symptoms, which if looked at closely enough could actually include the majority of the worlds population at one point or another in their lives.

The study is being backed by a pro-drug advocacy group in Florida whose leader confessed to the St. Petersburg Times that he has used ecstasy many times, including recently.

Ecstasy is a dangerous drug with psychedelic and amphetamine components and was first synthesized by a pharmaceutical company in the early 1900s. Though the drug was largely promoted by the psychiatric community for its ‘therapeutic qualities, it was finally made illegal in 1985 due to increasing abuse and harmful effects.

Use of the illegal drug in the United States by teenagers and young adults surged around the turn of the century but it has declined over the last few years.

Narconon Arrowhead, a highly successful drug education and rehabilitation program based on the drug-free methodology of L. Ron Hubbard, aligns with organizations that promote abstinence through drug prevention. Narconon Arrowhead stresses the fact that ecstasy use is dangerous, and that all drugs have side effects.

Ecstasy is a Schedule I controlled substance categorized by the Drug Enforcement Administration, meaning that it has been declared to have no medical use. Ecstasy is extremely damaging and withdrawal symptoms include severe depression. Other side effects include hyperthermia, involuntary teeth clenching, altered perceptions and a false sense of empathy.

Every person in America is affected by drug use, whether by paying for public health costs or due to themselves or a family member becoming addicted. The fact that some people insist on promoting dangerous drugs, regardless of any supposed value, sends the wrong message to our nations youth.

For more information about ecstasy, visit www.ecstasyaddiction.com. To get help for a loved one in need contact Narconon Arrowhead at 1-800-468-6933 or log on to www.stopaddiction.com.

# # #

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Luke Catton
NARCONON ARROWHEAD
918-339-5821
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright